Lightlake Therapeutics Inc. (LLTP)’ Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting
5/23/2013
More...
|
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Asthma Drug Seen as Potential Game Changer
5/22/2013
More...
|
Verona Pharma Release: Further Clinical Data Highlighting the Significant Bronchodilator Activity of Novel Dual PDE3/4 Inhibitor RPL554 Presented at American Thoracic Society International Conference
5/21/2013
More...
|
TRANSGENE (TRGNY) Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
5/21/2013
More...
|
Safety Results From Auris Medical AG's Clinical Development of AM-101 Presented at International Conference
5/17/2013
More...
|
Verona Pharma to Present Clinical and Pre-Clinical Data Highlighting the Significant Bronchodilator Activity of Novel Dual PDE3/4 Inhibitor RPL554 at Upcoming American Thoracic Society International Conference
5/16/2013
More...
|
New Data to be Presented at the 2013 American Society of Clinical Oncology Annual Meeting Show Active Biotech AB (BTPC)'s Commitment to Oncology Research
5/16/2013
More...
|
GENFIT Corp. (ALGFT) Release: GFT505 Reduces the Risk of Cardiovascular Events Through Its Action on Remnant Cholesterol
5/15/2013
More...
|
MorphoSys AG Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma
5/13/2013
More...
|
BioTie Therapies Corp. Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dependence
5/10/2013
More...
|
Opsona Therapeutics Ltd. Initiates a Phase II Study With OPN-305, a First-in Class Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
5/7/2013
More...
|
FDA Grants Breakthrough Status to Johnson & Johnson (JNJ), Genmab A/S (GEN.CO) Cancer Drug
5/7/2013
More...
|
Verona Pharma Release: Clinical and Scientific Advisory Board Formed to Help Guide Future Development of RPL554
4/29/2013
More...
|
MorphoSys AG Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell Acute Lymphoblastic Leukemia
4/26/2013
More...
|
AbbVie (ABBV) Hepatitis C Drugs Knock Out Virus at Eight Weeks
4/25/2013
More...
|
Medgenics, Inc. Reports "Encouraging" Data From Epodure Biopump Trial
4/25/2013
More...
|
Galapagos NV (GLPG.BR) Starts Phase 2A Study With GLPG0974 in Ulcerative Colitis
4/23/2013
More...
|
BioInvent (BOVNF) Initiates Clinical Trial With BI-505 in Smoldering Myeloma
4/22/2013
More...
|
TiGenix: Positive Phase IIa Study Results in Refractory Rheumatoid Arthritis With Allogeneic Stem Cell Product Cx611
4/22/2013
More...
|
Galapagos NV (GLPG.BR) Discovers Novel Candidate Drug to Treat Breast Cancer
4/22/2013
More...
|
Astellas Pharma Inc. (YPH.BE), GlaxoSmithKline (GSK) Vie to Make "High Altitude" Anemia Pill
4/22/2013
More...
|
Immune Targeting Systems (ITS) Ltd. Announces Positive Phase 2a Data in the at Risk Elderly Population With Flunisyn™, Its Pan-Strain Influenza a T-Cell Vaccine, and Two UK Biomedical Catalyst Grants for Chronic Hepatitis B and Oncology
4/17/2013
More...
|
Alkermes plc (ALKS) Has Jumped to a New High on Study Results
4/17/2013
More...
|
Galapagos NV (GLPG.BR) Presents Scope of GLPG0634 Phase 2b Program
4/16/2013
More...
|
Early Results of Activartis Biotech GmbH AV0113 Cancer Immunotherapy in Glioblastoma Trial Reveal Promising Trend
4/11/2013
More...
|
SALVAT and Kwang Dong Pharmaceutical Announced Positive Results of Phase IIb for Tarafenacin for Overactive Bladder Treatment
4/10/2013
More...
|
PhotoCure Announces Positive Final Results of Phase 2b Cevira ® Study
4/10/2013
More...
|
GlaxoSmithKline (GSK) Muscular Dystrophy Drug Reaches Primary Objective in Study
4/10/2013
More...
|
Merrimack Pharmaceuticals Inc. Lung Cancer Drug Fails in One Mid-Stage Trial Group
4/5/2013
More...
|
Starpharma Holdings Ltd Release: VivaGel® Study Demonstrates Reduced Risk of Recurrent BV
4/4/2013
More...
|
Aspireo Pharmaceuticals Reports Somatoprim Phase IIa Proof of Concept Results in Acromegaly
4/3/2013
More...
|
PRANA Biotechnology (PRAN) Provides Clinical Trials Safety and Progress Update
4/3/2013
More...
|
P2 Study Shows Effectiveness of Axelar AB's AXL-003
4/3/2013
More...
|
Convergence Pharmaceuticals Announces Successful Interim Data From Ground-Breaking Phase II Trigeminal Neuralgia Study
3/27/2013
More...
|
Galapagos NV (GLPG.BR) to Start Phase 2a Study With GLPG0974 in IBD Patients
3/27/2013
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
3/27/2013
More...
|
Addex Therapeutics (ADXN.SW) Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology
3/22/2013
More...
|
GlaxoSmithKline (GSK)'s Malaria Vaccine Ineffective Over Time
3/22/2013
More...
|
BioTie Therapies Corp. Presents Tozadenant Phase 2b Data at American Academy of Neurology Annual Meeting
3/21/2013
More...
|
BrainStorm Cell Therapeutics Inc. Release: Results of NurOwn™ Clinical Trial Suggest Efficacy in ALS Patients
3/21/2013
More...
|
Proteo Inc. (PTEO.OB) /Proteo Biotech AG (PTEO.OB): FDA Grants Orphan Drug Designation to Elafin for Prevention of Inflammatory Complications of Transthoracic Esophagectomy
3/21/2013
More...
|
Summit Corporation Outlines Clinical Development Plans for Utrophin Modulator Program for Duchenne Muscular Dystrophy
3/21/2013
More...
|
Taiwan Liposome Company's Liver Cancer Drug Put on Fast Track in China
3/19/2013
More...
|
FDA Deems Novartis AG (NVS) Lung Cancer Drug a "Breakthrough Therapy"
3/19/2013
More...
|
Phase II ALS Clinical Trial With BrainStorm Cell Therapeutics Inc.'s NurOwn™ to be Expanded to a Third Premiere U.S. Clinical Site
3/18/2013
More...
|
Trophos Launches First Study of Olesoxime in Multiple Sclerosis Patients
3/14/2013
More...
|
Orion Pharma's Alzheimer's Drug Add-On Brings Some Memory Improvement
3/12/2013
More...
|
Genmab, Inc. (GEN.CO), Roche (RHHBY) Drug Reduces Damage to Heart Muscle During Angioplasty
3/11/2013
More...
|
Telormedix Enrolls First Patient for Phase II in Bladder Cancer
3/11/2013
More...
|
PRANA Biotechnology (PRAN) Details Data Showing That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation
3/8/2013
More...
|
SymBio Pharmaceuticals Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
3/6/2013
More...
|
Gilead Sciences, Inc. (GILD)-Medivir AB (MVIRb.F) Hepatitis C Drug Clears Virus in Patients
3/5/2013
More...
|
PRANA Biotechnology (PRAN) Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation
3/4/2013
More...
|
PsiOxus Therapeutics Limited Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102
3/4/2013
More...
|
Chroma Therapeutics Release: Tosedostat Opal Study in Acute Myeloid Leukemia Published in Lancet Oncology
3/4/2013
More...
|
GlaxoSmithKline (GSK) DMD Drug Tied to Serious Side Effects, Hospitalizations
3/4/2013
More...
|
Prima Biomed (PRR.AX) Commences "CANVAS" Clinical Trial in Europe
2/28/2013
More...
|
Trophos Announces Positive Interim Review in Pivotal Study of Olesoxime in Spinal Muscular Atrophy
2/28/2013
More...
|
Kiadis Pharma Receives Regulatory Approval From Health Canada for a Phase II Clinical Study With Its Blood Cancer Treatment ATIR™
2/26/2013
More...
|
Immune Pharmaceuticals Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis
2/21/2013
More...
|
Luye Pharma Group Ltd. Completes US Phase II Trial of Cardiovascular TCM
2/19/2013
More...
|
Phytopharm PLC (PYM.L) Hit by Failure of Parkinson's Drug
2/19/2013
More...
|
Genmab A/S (GEN.CO) Rises as Danske Sees FDA Breakthrough
2/15/2013
More...
|
Ferring Pharmaceuticals, Inc. Release: In Patients With Active, Left-Sided Ulcerative Colitis, Study Shows Once-Daily Dose of Mesalazine Granules Provided Similar Results to Twice-Daily Dose
2/14/2013
More...
|
BioAlliance Pharma Announces the Forthcoming Extension of Its Phase II Clinical Trial With Validive® in the United States
2/14/2013
More...
|
Ablynx' Anti-IL-6R Nanobody, ALX-0061, Shows Excellent 24 Week Safety and Efficacy Results in a Phase II Clinical Trial in Rheumatoid Arthritis
2/13/2013
More...
|
Recipharm AB Supplies Clinical Trial Material for FDA Approved Phase IIb Study Sponsored by PledPharma
2/12/2013
More...
|
Critical Pharmaceuticals Limited Announces Successful Completion of Second Clinical Trial on CP024 Intranasal Growth Hormone
2/12/2013
More...
|
Galapagos NV (GLPG.BR) Announces GSK2586184 JAK1 Molecule Progresses to Phase 2 Studies
2/5/2013
More...
|
Aeras/Oxford University Development of TB Vaccine Hits Snag
2/5/2013
More...
|
BioLineRx Ltd. Provides Clarification Regarding Interim Analysis of CLARITY Trial for BL-1020
2/4/2013
More...
|
Mesoblast Limited Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis
1/30/2013
More...
|
New Clinical Study With Diamyd Medical AB's Diabetes Vaccine
1/30/2013
More...
|
AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir
1/29/2013
More...
|
Results From Active Biotech AB (BTPC)'s Phase II/III ANYARA Trial for the Treatment of Renal Cell Cancer
1/28/2013
More...
|
Medivir AB (MVIRb.F) Release: Phase II All-Oral Combination Studies of Simeprevir, TMC647055 and IDX719 for the Treatment of Hepatitis C to be Initiated Shortly
1/28/2013
More...
|
Shenzhen Neptunus Interlong Bio-Techique Co. Ltd. Files for U.S. Test of TCM
1/18/2013
More...
|
Pluristem Therapeutics (PSTI) Receives Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Germany
1/15/2013
More...
|
ArQule, Inc. (ARQL), Daiichi Sankyo, Inc. (4568.t)'s Colorectal Cancer Drug Fails Trial
1/14/2013
More...
|
Mesoblast Limited Soars on Spinal Fusion Success
1/11/2013
More...
|
Theravance, Inc. (THRX) and Alfa Wasserman Announce Initiation of Phase 2 Study With Velusetrag for Gastroparesis
1/9/2013
More...
|
BioLineRx Ltd. to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug During Week of March 18, 2013
1/7/2013
More...
|
BrainStorm Cell Therapeutics Inc.'s Clinical Trial is Fast-Tracked to Phase IIa, Representing a Major Milestone for the Company
1/7/2013
More...
|
Invion Limited Announces Initiation of Phase II Asthma Trial
1/7/2013
More...
|
Telormedix Granted IND for Phase II in Bladder Cancer
1/7/2013
More...
|
BioTie Therapies Corp. Reports Top-Line Data From Clinical Study With Nepicastat (SYN117) in Post-Traumatic Stress Disorder
12/27/2012
More...
|
Addex Therapeutics (ADXN.SW) Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor
12/20/2012
More...
|
TiGenix: Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells
12/19/2012
More...
|
PRANA Biotechnology (PRAN) Completes Recruitment in Huntington Trial
12/19/2012
More...
|
Biotech Venture Fund's Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed From Sequella, Inc.
12/19/2012
More...
|
Invion Limited Progress Update: Inv102 Phase 2 Clinical Programs
12/19/2012
More...
|
AstraZeneca PLC (AZN) Arthritis Drug Performs Badly Under Tests
12/17/2012
More...
|
Medivir AB (MVIRb.F) Announces Initiation of the Second Cohort of the Interferon-Free Phase II Study Combining Simeprevir and Sofosbuvir for Hepatitis C Treatment
12/13/2012
More...
|
Celgene International Sárl (CELG) Release: Data Evaluating Combination Treatments Including REVLIMID® Plus Antibody Therapies in Patients With Various Difficult-to-Treat Forms of Non-Hodgkin Lymphoma Presented at the 54th American Society of Hematology Annual Meeting
12/12/2012
More...
|
Positive Results Achieved in Vernalis PLC (VNLPY.PK)' Receptor Occupancy Study of V8144 for Parkinson's Disease and Other CNS Indications
12/12/2012
More...
|
BioTie Therapies Corp.'s Tozadenant (SYN115) Meets Primary and Multiple Secondary Endpoints in Phase 2b Study in Parkinson's Disease
12/11/2012
More...
|
Celgene International Sárl (CELG) Release: Results of Pivotal Study (MCL-001) Evaluating REVLIMID in Mantle-Cell Lymphoma Presented at 54th American Society of Hematology Annual Meeting
12/11/2012
More...
|
BioTie Therapies Corp.'s Tozadenant (SYN115) Meets Primary and Multiple Secondary Endpoints in Phase 2b
12/11/2012
More...
|
Sanofi (France) (SAN.PA)'s JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
12/10/2012
More...
|
AOP Orphan Pharmaceuticals AG Reports Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera (PV)
12/10/2012
More...
|
Bionor Pharma ASA Release: Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial
12/5/2012
More...
|
Sol-Gel Technologies Completes Successful Phase II Study in Rosacea
12/5/2012
More...
|
NOXXON Pharma AG Initiates Phase IIa of Anti-Hepcidin Spiegelmer® NOX-H94
12/4/2012
More...
|
AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) and Astellas Pharma Inc. (YPH.BE) Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer
12/3/2012
More...
|
PRANA Biotechnology (PRAN) Completes Recruitment in Alzheimer's Trial
11/27/2012
More...
|
Neovacs SA: Final Results of the Phase II Study in Crohn's
11/20/2012
More...
|
Atox Bio Reports Positive Tissue Infection Trial Results
11/20/2012
More...
|
Elorac, Inc. Announces Orphan Designation in Europe for Novel Topical Treatment for Cutaneous T-Cell Lymphoma (CTCL)
11/16/2012
More...
|
Threshold Pharmaceuticals, Inc. (THLD) Reports Updated Phase 2 Results Including Analysis of Maintenance Therapy With TH-302 Following Induction Therapy With TH-302 Plus Doxorubicin in Soft Tissue Sarcoma
11/15/2012
More...
|
Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment for Metastatic Pancreatic Cancer
11/13/2012
More...
|
Galapagos NV (GLPG.BR) Release: GLPG0634 Phase 2A Multicenter Trial Shows Dose-Response, Confirms Excellent Safety and Significant Clinical Benefit in Rheumatoid Arthritis Patients
11/8/2012
More...
|
Moberg Derma Initiates New Study of MOB-015
11/8/2012
More...
|
Long-Term Immunomodulation Induced by Anergis' COP Allergy Vaccine AllerT Now Extends to the 4th Year After Treatment
11/8/2012
More...
|
Anergis Starts European Phase IIb Clinical Trial With AllerT in Patients With Moderate to Severe Allergy to Birch Pollen
11/6/2012
More...
|
Aspireo Pharmaceuticals Starts Somatoprim Phase IIa Study in Acromegaly Patients
11/6/2012
More...
|
Addex Therapeutics (ADXN.SW) Reports Top-line Data From a Successful Phase 2a Clinical Study With ADX71149 in Schizophrenia Patients
11/5/2012
More...
|
Hutchison Medipharma Starts Clinical Trial on Fourth Cancer Drug
11/2/2012
More...
|
Vertex Pharmaceuticals (MA) (VRTX) Joins GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) in Testing Hepatitis C Combos
11/2/2012
More...
|
Orexo AB Announces Dosing of First Patient With OX51 in Phase II Clinical Trial on Prevention of Procedure-Induced Pain
10/30/2012
More...
|
Orion Corporation Receives Positive Phase II Study Results of a New Levodopa Product for Parkinson's Disease
10/24/2012
More...
|
BioLineRx Ltd. to Conduct Interim Analysis of Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia
10/24/2012
More...
|
Cytheris SA Announces U.S. Orphan Drug Designation for CYT107 for the Treatment of Progressive Multifocal Leucoencephalopathy (PML)
10/24/2012
More...
|
Teva Pharmaceutical Industries Limited (TEVA) Reports Success in Laquinimod Study for Crohn's Disease
10/22/2012
More...
|
ViroStatics AV-HALT Phase 2a Study in HIV/AIDS Paper Published in PLoS ONE
10/22/2012
More...
|
Active Biotech AB (BTPC)'s Partner Ipsen (IPN.PA) Initiates a Proof-of-Concept Study With Tasquinimod in Additional Cancer Indications
10/19/2012
More...
|
Prima Biomed (PRR.AX)'s Cancer Treatment Finds Success in Trial
10/15/2012
More...
|
BioLineRx Ltd. Announces New Analysis of EAGLE Phase IIb Study Showing a Significantly Greater Beneficial Effect of BL-1020 on Cognitive Function in Schizophrenia Patients
10/9/2012
More...
|
Merck & Co., Inc. (MRK)'s Once-a-Week Diabetes Drug Effective in Clinical Study
10/4/2012
More...
|
Eli Lilly and Company (LLY) and Boehringer Ingelheim Corporation Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue
10/3/2012
More...
|
Active Biotech AB (BTPC), Ipsen (IPN.PA) Initiate a Phase II "Switch Maintenance" Trial in Metastatic Castrate-Resistant Prostate Cancer With Tasquinimod
10/3/2012
More...
|
Ipsen (IPN.PA) Initiates a Phase II "Switch Maintenance" Trial in Metastatic Castrate-Resistant Prostate Cancer With Tasquinimod
10/3/2012
More...
|
Bavarian Nordic (BAVA.CO) Reports Preliminary Data From Phase 2 Trial of CV-301 in Metastatic Breast Cancer
10/1/2012
More...
|
Synta Pharmaceuticals Release: Updated Results From Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival From the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer
10/1/2012
More...
|
GlaxoSmithKline (GSK) Two-Drug Melanoma Combo Slows Cancer in Study
10/1/2012
More...
|
UCB, Inc. (UCBJF.PK)'s RA Drug Does Not Overly Impress in Phase II
10/1/2012
More...
|
Novartis AG (NVS) Says Psoriasis Drug Trial Results Positive
9/28/2012
More...
|
BioLineRx Ltd. Announces Publication of EAGLE Study Results Demonstrating BL-1020's Efficacy in Improving Cognitive Function in Schizophrenia Patients
9/27/2012
More...
|
NOXXON Pharma AG Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer®
9/26/2012
More...
|
Medivir AB (MVIRb.F): a Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
9/20/2012
More...
|
Bristol-Myers Squibb Company (BMY) Hepatitis C Drug Trial Turns Fatal for Patient
9/18/2012
More...
|
Addex Therapeutics (ADXN.SW) Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients With Anxiety Symptoms
9/17/2012
More...
|
Jennerex, Inc. Presents Positive Phase 2 Trial of JX-594
9/17/2012
More...
|
Oncolytics Biotech Inc. (ONC.TO) Lung Cancer Drug Meets Main Goal in Mid-Stage Trial
9/13/2012
More...
|
GlaxoSmithKline (GSK)'s Experimental Drug Curbs Smokers' Nicotine Cravings
9/12/2012
More...
|
Sanofi (France) (SAN.PA) Dengue Vaccine Less Effective Than Hoped
9/12/2012
More...
|
Hybrigenics Starts Phase II Clinical Trial of Inecalcitol in Chronic Lymphocytic Leukemia
9/11/2012
More...
|
FDA Grants Fast Track Designation to Atox Bio's AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI)
9/10/2012
More...
|
Moberg Derma: Recruitment Completed for Limtop Phase II Study in AK
9/6/2012
More...
|
GlaxoSmithKline (GSK) Studies Three-in-One Emphysema Medicine to Keep Ahead of the Pack
9/5/2012
More...
|
Cellceutix (CTIX) Anti-Psoriasis Drug Advances Toward Phase 2 Clinical Trials With Selection of Dr. Reddy's Laboratories Ltd. (RDY)'s for Manufacturing
9/4/2012
More...
|
GenSpera Obtains Authorization for G-202 Phase II Trial in the United Kingdom
9/4/2012
More...
|
BioLineRx Ltd. In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers
9/4/2012
More...
|
Elan Corporation PLC (ELN) Announces Dosing of First Patient in Phase 2 Trial of ELND005 (Scyllo-inositol) in Bipolar Disorder
8/30/2012
More...
|
Spinifex Pharmaceuticals Pty Limited Announces Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia
8/28/2012
More...
|
Resverlogix Corporation (RVX.TO) Rises on Heart Drug Study Results
8/28/2012
More...
|
New Novartis AG (NVS) Drug Shows Potential in Heart Failure
8/27/2012
More...
|
PRANA Biotechnology (PRAN) Provides Clinical Trials Update
8/22/2012
More...
|
Symphogen A/S Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD Journal
8/22/2012
More...
|
Unigene Laboratories, Inc. (UGNE) and Nordic Bioscience A/S Announce Preliminary Selection of Lead Compound for Treating Type 2 Diabetes
8/16/2012
More...
|
AstraZeneca PLC (AZN), BTG plc (BGC.L) Scrap Sepsis Drug as Trial Fails
8/9/2012
More...
|
TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study
8/8/2012
More...
|
TWi Pharmaceuticals, Inc. Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients With Type 2 Diabetes
8/8/2012
More...
|
Royal Philips Electronics N.V. (PHG) and Celsion Corporation (CLN) Announce FDA Clearance to Commence Phase II Study of ThermoDox(R) and MR-Guided HIFU in Bone Cancer
8/7/2012
More...
|
DBV Technologies Initiates VIPES Phase IIb Clinical Study, the First Global Trial Ever in Desensitization of Peanut-Allergic Children and Adults
8/2/2012
More...
|
Prima Biomed (PRR.AX) to Release Interim CVac Clinical Data
7/30/2012
More...
|
Apogenix: APG101 Exceeds Expectations With Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma
7/26/2012
More...
|
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella, Inc.'s Antibiotic, SQ109, for Tuberculosis
7/26/2012
More...
|
Sanofi (France) (SAN.PA)'s World First Dengue Vaccine Beats 3 Virus Strains
7/26/2012
More...
|
Bionor Pharma ASA's Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic "Boosts" That Could Result in New Treatment Option for People Living With HIV/AIDS
7/20/2012
More...
|
NOXXON Pharma AG Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer® NOX-A12 for Treatment of Chronic Lymphocytic Leukemia
7/11/2012
More...
|
Blow for BioInvent (BOVNF) as Vascular Treatment Fails
7/11/2012
More...
|
Cytheris SA Announces CYT107 Orphan Drug Designation in Europe for the Treatment of Progressive Multifocal Leucoencephalopathy (PML)
7/10/2012
More...
|
Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at World Federation of Hemophilia 2012 World Congress
7/9/2012
More...
|
BioTie Therapies Corp. Completes Enrollment in Phase 2b Trial of Tozadenant in Parkinson's Disease
7/5/2012
More...
|
Diamyd Medical AB Reports Results from Phase II Study in Cancer Pain
7/3/2012
More...
|
Medivir AB (MVIRb.F) Announces an Interferon-Free Phase II Combination Trial With TMC435 and Daclatasvir to Commence Shortly
6/29/2012
More...
|
Bioxyne (BXN) Reports the Results from the Phase IIb Study
6/28/2012
More...
|
GlobeImmune, Inc.'s GI-4000 in Combination With Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial With Ras Mutation Positive Pancreas Cancer
6/27/2012
More...
|
Key Results from Auris Medical AG's Phase IIb Study of AM-101 in Acute Inner Ear Tinnitus Presented at International Conference
6/26/2012
More...
|
Flamel Technologies (FLML) Medusa(R)-Formulated Interferon-Alpha Demonstrates Favorable Antiviral Activity and Safety in a Phase 2 Clinical Study
6/25/2012
More...
|
Ablynx Announces New Compelling Results on Ozoralizumab (ATN-103) in Rheumatoid Arthritis
6/25/2012
More...
|
Starpharma Holdings Ltd Release: Full Enrolment Achieved for BV Phase 2 Trial and First Phase 3 Trial
6/25/2012
More...
|
Addex Therapeutics (ADXN.SW) to Present Phase 2a Dipraglurant Data at Movement Disorder Society's International Congress
6/19/2012
More...
|
NOXXON Pharma AG Initiates Phase IIa of anti-CCL2/MCP-1 Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy
6/19/2012
More...
|
ERYtech Pharma Announces the Oral Presentation of Positive Phase II Clinical Trial Results in Acute Lymphoblastic Leukemia
6/18/2012
More...
|
Glycotope Moves PankoMab™ Towards Phase-II Clinical Development
6/15/2012
More...
|
Biomay AG Release: Innovative Grass Pollen Allergy Vaccine Shows Efficacy in Phase IIA Trial
6/14/2012
More...
|
ERYtech Pharma's Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency
6/13/2012
More...
|
AB Science (AB.PA) Release: Masitinib Treatment of Progressive Multiple Sclerosis Publication in BMC Neurology
6/13/2012
More...
|
Karolinska Development AB: Pharmanest Initiates Phase II Study of SHACT
6/12/2012
More...
|
Boehringer Ingelheim Corporation Release: New Data Demonstrate Sustained Glucose Reduction and Weight Loss Up to 90 Weeks With Investigational SGLT-2 Inhibitor, Empagliflozin*
6/11/2012
More...
|
ArQule, Inc. (ARQL)/Daiichi Sankyo, Inc. (D4S.F) Report Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma Presented at American Society of Clinical Oncology
6/11/2012
More...
|
Otsuka Pharmaceutical Co., Ltd.'s Experimental TB Drug Fights Resistant Disease
6/8/2012
More...
|
Glycotope Moves FSH-GEX™ into Phase-II Clinical Development
6/8/2012
More...
|
Verva Pharmaceuticals Announces Results of Successful VVP808-002 Phase 2 Clinical Trial in Type 2 Diabetes and Outcome of Annual General Meeting
6/6/2012
More...
|
Interim Results from Neovacs SA' Phase II Clinical Trial in Crohn's Disease
6/5/2012
More...
|
BioInvent (BOVNF), ThromboGenics NV (TBGNF) Plunges as Development of Anticoagulent is Dropped
6/5/2012
More...
|
Addex Therapeutics (ADXN.SW) Partner to Initiate Phase 2 Clinical Trial of ADX71149 for the Treatment of Major Depressive Disorder With Anxiety Symptoms
6/5/2012
More...
|
Active Biotech AB (BTPC), Ipsen Present Encouraging OS Data from Tasquinimod Phase II Study in CRPC
6/4/2012
More...
|
Canbas Co., Ltd.: CBP501 Met Primary Endpoint of Phase II Study in Malignant Pleural Mesothelioma
6/4/2012
More...
|